News

Partner companies' news

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis
HANOVER, MD, April 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage bioph...
Acorn Management Partners, Administrator
— April 2022 — 422 views PCSA

Motorsport Games Reports Fourth Quarter & Full Year 2021 Financial Results
MIAMI, March 30, 2022 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or the “Company”) today reported financial result...
Acorn Management Partners, Administrator
— April 2022 — 468 views MSGM

Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update
HANOVER, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage compa...
Acorn Management Partners, Administrator
— April 2022 — 426 views PCSA

Motorsport Games’ rFactor 2 Becomes the Official Sim Racing Platform of Formula E
MIAMI, March 28, 2022 (GLOBE NEWSWIRE) -- None [1]*Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games”)* , a leading racing game developer, pub...
Acorn Management Partners, Administrator
— March 2022 — 501 views MSGM

Motorsport Games Partners with Romain Grosjean to Assist in the Development of rFactor 2 and esports Events
MIAMI, March 25, 2022 (GLOBE NEWSWIRE) -- None [1]*Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games”)* , a leading racing game developer, pub...
Acorn Management Partners, Administrator
— March 2022 — 461 views MSGM

Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST
HANOVER, MD, March 23, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing...
Acorn Management Partners, Administrator
— March 2022 — 419 views PCSA

Motorsport Games to Report Fourth Quarter & Full Year 2021 Financial Results
MIAMI, March 16, 2022 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games”), a leading racing game developer, publisher and ...
Acorn Management Partners, Administrator
— March 2022 — 405 views MSGM

Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference
HANOVER, MD, March 10, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage bioph...
Acorn Management Partners, Administrator
— March 2022 — 436 views PCSA

Motorsport Games Announces Next Gen Car For NASCAR 21: Ignition
MIAMI, Feb. 15, 2022 (GLOBE NEWSWIRE) -- None [1]*Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games”)* , a leading racing game developer, publ...
Acorn Management Partners, Administrator
— February 2022 — 491 views MSGM

Motorsport Games and Adam Breeden announce global agreement with Formula 1® to create next-level competitive socialising experience, launching in London in 2022
MIAMI, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Adam Breeden, the pioneer of competitive socialising in the UK and entrepreneurial force behind some of the...
Acorn Management Partners, Administrator
— February 2022 — 435 views MSGM

Motorsport Games Announces rFactor 2 Content Update and User Interface Refresh
MIAMI, Feb. 07, 2022 (GLOBE NEWSWIRE) -- None [1]*Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games”)* , a leading racing game developer, publ...
Acorn Management Partners, Administrator
— February 2022 — 432 views MSGM

Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities
FRAMINGHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
Acorn Management Partners, Administrator
— January 2022 — 454 views ARTH

Arch Therapeutics Announces Appointment of Guy Fish to the Board
FRAMINGHAM, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
Acorn Management Partners, Administrator
— January 2022 — 539 views ARTH

Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System
FRAMINGHAM, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
Acorn Management Partners, Administrator
— December 2021 — 510 views ARTH

Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program
FRAMINGHAM, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
Acorn Management Partners, Administrator
— December 2021 — 502 views ARTH

About us

Helping America invest in you:

Connecting your company stock with professional market participants.

One call at a time

Stay updated :

Participate on our social stream.

Our Blogs

Tags

Archives